BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy

Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Sancho, Mónica, Orzáez, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849717/
https://www.ncbi.nlm.nih.gov/pubmed/33553610
http://dx.doi.org/10.1080/23723556.2020.1859918
_version_ 1783645353471377408
author Sancho, Mónica
Orzáez, Mar
author_facet Sancho, Mónica
Orzáez, Mar
author_sort Sancho, Mónica
collection PubMed
description Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovarian killer (BOK) induces cell death, thereby suggesting a new target site for anti-tumorigenic strategies.
format Online
Article
Text
id pubmed-7849717
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78497172021-02-05 BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy Sancho, Mónica Orzáez, Mar Mol Cell Oncol Author’s Views Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovarian killer (BOK) induces cell death, thereby suggesting a new target site for anti-tumorigenic strategies. Taylor & Francis 2021-01-11 /pmc/articles/PMC7849717/ /pubmed/33553610 http://dx.doi.org/10.1080/23723556.2020.1859918 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Sancho, Mónica
Orzáez, Mar
BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
title BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
title_full BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
title_fullStr BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
title_full_unstemmed BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
title_short BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
title_sort bok-mcl1 transmembrane interactions: a challenging target for cancer therapy
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849717/
https://www.ncbi.nlm.nih.gov/pubmed/33553610
http://dx.doi.org/10.1080/23723556.2020.1859918
work_keys_str_mv AT sanchomonica bokmcl1transmembraneinteractionsachallengingtargetforcancertherapy
AT orzaezmar bokmcl1transmembraneinteractionsachallengingtargetforcancertherapy

Ejemplares similares